Nivolumab plus PAI-1 inhibitor combined therapy for unresectable advanced melanoma: Phase II clinical trial

被引：0
|
作者：
Fujimura, T. [1 ]
Yoshino, K. [2 ]
Kato, H. [3 ]
Fukushima, S. [4 ]
Otsuka, A. [5 ]
Matsushita, S. [6 ]
Fujisawa, Y. [7 ]
Ishizuki, S. [8 ]
Kambayashi, Y. [1 ]
Asano, Y. [1 ]
机构：
[1] Tohoku Daigaku, Dermatol, Sendai, Miyagi, Japan
[2] Canc Inst Hosp Japanese Fdn Canc Res, Dermato Oncol, Tokyo, Japan
[3] Nagoya Shiritsu Daigaku, Dermatol, Nagoya, Aichi, Japan
[4] Kumamoto Daigaku, Dept Dermatol, Kumamoto, Kumamoto, Japan
[5] Kinki Daigaku, Dept Dermatol, Higashiosaka, Osaka, Japan
[6] Kokuritsu Byoin Kiko Kagoshima Iryo Ctr, Dermato Oncol, Kagoshima, Kagoshima, Japan
[7] Ehime Daigaku, Dermatol, Matsuyama, Ehime, Japan
[8] Tsukuba Daigaku, Dermatol, Tsukuba, Ibaraki, Japan
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
1194
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [41] Immunogene therapy of human melanoma - Phase I/II clinical trial
    Mackiewicz, A
    Kapcinska, M
    Wiznerowicz, M
    Malicki, J
    Nawrocki, S
    Nowak, J
    Murawa, P
    Sibilska, E
    Kowalczyk, D
    Lange, A
    Hawley, RC
    Rose-John, S
    GENE THERAPY OF CANCER, 1998, 451 : 557 - 560
  • [42] A phase II study of mFOLFOX6 plus nivolumab as initial therapy for patients with advanced esophageal squamouscell cancer: FLONTALE trial
    Kubota, Y.
    Ueyama, S.
    Yamamoto, Y.
    Amanuma, Y.
    Furuta, M.
    Sato, S.
    Tsushima, T.
    Moriwaki, T.
    Tanabe, K.
    Sunakawa, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S196 - S196
  • [43] A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer
    Sanoff, Hanna K.
    Deal, Allison M.
    Patel, Jai
    Sorah, Jonathan D.
    Gaddy, Jacquelyne
    O'Neil, Bert
    Turk, Anita
    Irvin, William
    Boles, Jeremiah
    Lee, Michael S.
    McRee, Autumn
    Wardell, Alexis C.
    Weck, Karen E.
    Basch, Ethan
    Wood, William A.
    Innocenti, Federico
    ONCOLOGIST, 2024, 29 (09): : 786 - 793
  • [44] Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial
    Rodrigues, Manuel
    Vanoni, Giulia
    Loap, Pierre
    Dubot, Coraline
    Timperi, Eleonora
    Minsat, Mathieu
    Bazire, Louis
    Durdux, Catherine
    Fourchotte, Virginie
    Laas, Enora
    Pouget, Nicolas
    Castel-Ajgal, Zahra
    Marret, Gregoire
    Lesage, Laetitia
    Meseure, Didier
    Vincent-Salomon, Anne
    Lecompte, Lolita
    Servant, Nicolas
    Vacher, Sophie
    Bieche, Ivan
    Malhaire, Caroline
    Huchet, Virginie
    Champion, Laurence
    Kamal, Maud
    Amigorena, Sebastian
    Lantz, Olivier
    Chevrier, Marion
    Romano, Emanuela
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [45] Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial
    Manuel Rodrigues
    Giulia Vanoni
    Pierre Loap
    Coraline Dubot
    Eleonora Timperi
    Mathieu Minsat
    Louis Bazire
    Catherine Durdux
    Virginie Fourchotte
    Enora Laas
    Nicolas Pouget
    Zahra Castel-Ajgal
    Gregoire Marret
    Laetitia Lesage
    Didier Meseure
    Anne Vincent-Salomon
    Lolita Lecompte
    Nicolas Servant
    Sophie Vacher
    Ivan Bieche
    Caroline Malhaire
    Virginie Huchet
    Laurence Champion
    Maud Kamal
    Sebastian Amigorena
    Olivier Lantz
    Marion Chevrier
    Emanuela Romano
    Nature Communications, 14
  • [46] Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib
    Amagai, Ryo
    Fujimura, Taku
    Kambayashi, Yumi
    Sato, Yota
    Tanita, Kayo
    Ohuchi, Kentaro
    Hashimoto, Akira
    Aiba, Setsuya
    JOURNAL OF DERMATOLOGY, 2020, 47 (06): : 654 - 657
  • [47] Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma
    Bedikian, AY
    Legha, SS
    Eton, O
    Buzaid, AC
    Papadopoulos, N
    Plager, C
    McIntyre, S
    Viallet, J
    ANTI-CANCER DRUGS, 1999, 10 (08) : 735 - 739
  • [48] Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: Phase II trial with correlative studies
    Slingluff, Craig L.
    Petroni, Gina R.
    Molhoek, Kerrington R.
    Brautigan, David L.
    Chianese-Bullock, Kimberly A.
    Shada, Amber L.
    Smolkin, Mark E.
    Gaucher, Alison
    Murphy, Cheryl F.
    Grosh, William W.
    Weiss, Geoffrey R.
    Wagenseller, Aubrey G.
    Olszanski, Anthony J.
    Martin, Lainie P.
    Shea, Sofia M.
    Erdag, Gulsun
    Ram, Prahlad T.
    Gershenwald, Jeffrey E.
    Weber, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trialA randomized clinical trial of neoadjuvant therapy for ESCC
    Yong Li
    Aiping Zhou
    Shuoyan Liu
    Ming He
    Keneng Chen
    Ziqiang Tian
    Yin Li
    Jianjun Qin
    Zhen Wang
    Haiquan Chen
    Hui Tian
    Yue Yu
    Wang Qu
    Liyan Xue
    Shun He
    Shuhang Wang
    Fenglong Bie
    Guangyu Bai
    Bolun Zhou
    Zhaoyang Yang
    Huiyao Huang
    Yan Fang
    Benjamin Li
    Xiangrong Dai
    Shugeng Gao
    Jie He
    BMC Medicine, 21
  • [50] Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
    Hodi, F. S.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. J.
    Rutkowski, P.
    Cowey, C. L.
    Lao, C.
    Schadendorf, D.
    Wagstaff, J.
    Dummer, R.
    Ferrucci, P. F.
    Smylie, M.
    Hill, A. G.
    Hogg, D.
    Marquez-Rodas, I.
    Jiang, J.
    Rizzo, J.
    Larkin, J.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 735 - 735
12345